Comparar compuestos

TB-500

Start

2 mg

Range

2–5 mg per week

Frequency

2× weekly (loading), then weekly

Cycle

4–6 week loading, then maintenance

Vials

5 / 10 mg

Ajuste gradual

1. Weeks 1–4: 2–2.5 mg, twice weekly
2. Weeks 5+: 2 mg, once weekly

BPC-157

Start

0.25 mg

Range

0.25–0.5 mg

Frequency

Once or twice daily

Cycle

4–8 weeks

Vials

5 / 10 mg

KPV

Viales

10 mg

Datos de dosis

Referencia de laboratorio; no indicado

TB-500

TB-500 has been analytically identified as the acetylated thymosin β4 residues 17–23 fragment, Ac-LKKTETQ; some suppliers also use that name for full-length 43-amino-acid thymosin β4. These are not interchangeable. The wound-repair findings below concern full-length thymosin β4, which binds G-actin and participates in cell migration; confirm the sequence of any supplier-labeled product.

BPC-157

BPC-157 is a 15-amino-acid fragment of a protein found in gastric juice. Preclinical studies associate it with increased growth-hormone-receptor expression, angiogenesis pathways (including VEGF-related signalling) and lower inflammatory cytokines. The exact receptor target is not established.

KPV

KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-MSH. It is taken up by the PepT1 transporter in gut and immune cells and inhibits NF-κB and MAP kinase inflammatory signalling.

TB-500

• In a rat full-thickness wound model, thymosin β4 increased re-epithelialisation by 42% at day 4 and up to 61% at day 7 vs saline.
• In the same full-length thymosin β4 study, treated wounds contracted at least 11% more by day 7, with more collagen deposition and new blood vessels.
• Full-length thymosin β4 increased keratinocyte migration 2–3-fold in cell-culture assays; this is not evidence for an arbitrary TB-500-labeled vial.

BPC-157

• A 2025 systematic review found 36 studies: 35 preclinical and 1 clinical.
• Animal models showed improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injuries.
• The only clinical study was a small retrospective series: 7 of 12 patients with chronic knee pain reported relief for more than 6 months.

KPV

• In mouse colitis models, oral KPV reduced intestinal inflammation and pro-inflammatory cytokine expression.
• An engineered oral KPV conjugate reached 3.8-fold higher colon levels than free KPV in colitic mice and was also anti-inflammatory in acute lung injury.

TB-500

• Most evidence is on full-length thymosin β4; data on the TB-500 fragment itself is limited.
• Not approved for human use; listed as prohibited by the World Anti-Doping Agency.

BPC-157

• Not FDA-approved for any use and listed as prohibited by the World Anti-Doping Agency.
• The cited human evidence does not establish systemic human pharmacokinetics; experimental clearance findings are not a validated human half-life for this research vial.
• Preclinical safety studies reported no organ toxicity, but the 2025 review found no clinical safety data.

KPV

• Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
• Evidence is from cell and mouse studies; no human trials are cited.

TB-500

3 referencias · ver

BPC-157

2 referencias · ver

KPV

2 referencias · ver